Persistent or repeated elevation of intraocular pressure (IOP) is a primary risk factor of visual field loss in glaucoma, therefore IOP reduction is the first-line therapeutic option in the disease management. Unfortunately, the current therapies are associated with a lot of deficiencies including several daily dosing, reduced efficacy and systemic side effects all of which resulted in poor patient compliance. Previously we have identified Calcium voltage-gated channel auxiliary subunit Alpha2delta 1 gene (Cacna2d1) as a novel modulator of IOP and confirmed that pregabalin targeted CACNA2D1 in eye tissues (ciliary body and trabecular meshwork) to lower IOP in a dose-dependent manner. The research presented in this dissertation aimed to develop a once-daily ocular pregabalin-loaded multiple water-in-oil-in-water microemulsion eye drops. Several in vitro and in vivo evaluations were used to characterize the prepared ophthalmic formulations. Also stability study at 5°C, 25°C, 30°C and 40°C was conducted for four months. All the formulations components were carefully selected to be highly biocompatible that provided a highly transparent eye drops with a miniscule droplet size (
","abstract_html":"<p>Persistent or repeated elevation of intraocular pressure (IOP) is a primary risk factor of visual field loss in glaucoma, therefore IOP reduction is the first-line therapeutic option in the disease management. Unfortunately, the current therapies are associated with a lot of deficiencies including several daily dosing, reduced efficacy and systemic side effects all of which resulted in poor patient compliance. Previously we have identified Calcium voltage-gated channel auxiliary subunit Alpha2delta 1 gene (<em>Cacna2d1</em>) as a novel modulator of IOP and confirmed that pregabalin targeted CACNA2D1 in eye tissues (ciliary body and trabecular meshwork) to lower IOP in a dose-dependent manner. The research presented in this dissertation aimed to develop a once-daily ocular pregabalin-loaded multiple water-in-oil-in-water microemulsion eye drops. Several in vitro and in vivo evaluations were used to characterize the prepared ophthalmic formulations. Also stability study at 5°C, 25°C, 30°C and 40°C was conducted for four months. All the formulations components were carefully selected to be highly biocompatible that provided a highly transparent eye drops with a miniscule droplet size (</p>","abstract_has_math":false,"creators":["Maria, Doaa Nabih Ahmed"],"institution":null,"degree_name":"Doctor of Philosophy (PhD)","degree_level":"Dissertation","degree_discipline":"Pharmaceutical Sciences","degree_department":null,"school":null,"contributors":["Jablonski , Monica M., PhD"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2018,"date_issued":"2018-12-01T08:00:00Z","date_published":"2018-12-01T08:00:00Z","updated_at":"2026-07-24T05:00:33Z","subjects":["Dutch belted rabbits","Glaucoma","Intraocular pressure","Microemulsion","Stability","Transcorneal permeability","Medicinal and Pharmaceutical Chemistry","Medicine and Health Sciences","Pharmaceutics and Drug Design","Pharmacy and Pharmaceutical Sciences"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"https://dc.uthsc.edu/dissertations/466","outbound_label":"Repository record","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Jablonski , Monica M., PhD"]},{"key":"dc:creator","label":"Author","values":["Maria, Doaa Nabih Ahmed"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.available","label":"Dc Date Available","values":["2020-12-12T08:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Pharmaceutical Sciences"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Dissertation"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Doctor of Philosophy (PhD)"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Dutch belted rabbits","Glaucoma","Intraocular pressure","Microemulsion","Stability","Transcorneal permeability","Medicinal and Pharmaceutical Chemistry","Medicine and Health Sciences","Pharmaceutics and Drug Design","Pharmacy and Pharmaceutical Sciences"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://dc.uthsc.edu/dissertations/466"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Persistent or repeated elevation of intraocular pressure (IOP) is a primary risk factor of visual field loss in glaucoma, therefore IOP reduction is the first-line therapeutic option in the disease management. Unfortunately, the current therapies are associated with a lot of deficiencies including several daily dosing, reduced efficacy and systemic side effects all of which resulted in poor patient compliance. Previously we have identified Calcium voltage-gated channel auxiliary subunit Alpha2delta 1 gene (Cacna2d1) as a novel modulator of IOP and confirmed that pregabalin targeted CACNA2D1 in eye tissues (ciliary body and trabecular meshwork) to lower IOP in a dose-dependent manner. The research presented in this dissertation aimed to develop a once-daily ocular pregabalin-loaded multiple water-in-oil-in-water microemulsion eye drops. Several in vitro and in vivo evaluations were used to characterize the prepared ophthalmic formulations. Also stability study at 5°C, 25°C, 30°C and 40°C was conducted for four months. All the formulations components were carefully selected to be highly biocompatible that provided a highly transparent eye drops with a miniscule droplet size (
"]},{"key":"dc:title","label":"Title","values":["Development of Multiple Microemulsion Eye Drops for Sustained Release of New Glaucoma Drug"]}]}],"canonical_facts":{"dc:contributor":["Jablonski , Monica M., PhD"],"dc:creator":["Maria, Doaa Nabih Ahmed"],"dc:date.available":["2020-12-12T08:00:00Z"],"dc:description.abstract":["Persistent or repeated elevation of intraocular pressure (IOP) is a primary risk factor of visual field loss in glaucoma, therefore IOP reduction is the first-line therapeutic option in the disease management. Unfortunately, the current therapies are associated with a lot of deficiencies including several daily dosing, reduced efficacy and systemic side effects all of which resulted in poor patient compliance. Previously we have identified Calcium voltage-gated channel auxiliary subunit Alpha2delta 1 gene (Cacna2d1) as a novel modulator of IOP and confirmed that pregabalin targeted CACNA2D1 in eye tissues (ciliary body and trabecular meshwork) to lower IOP in a dose-dependent manner. The research presented in this dissertation aimed to develop a once-daily ocular pregabalin-loaded multiple water-in-oil-in-water microemulsion eye drops. Several in vitro and in vivo evaluations were used to characterize the prepared ophthalmic formulations. Also stability study at 5°C, 25°C, 30°C and 40°C was conducted for four months. All the formulations components were carefully selected to be highly biocompatible that provided a highly transparent eye drops with a miniscule droplet size (
"],"dc:identifier":["https://dc.uthsc.edu/dissertations/466"],"dc:subject":["Dutch belted rabbits","Glaucoma","Intraocular pressure","Microemulsion","Stability","Transcorneal permeability","Medicinal and Pharmaceutical Chemistry","Medicine and Health Sciences","Pharmaceutics and Drug Design","Pharmacy and Pharmaceutical Sciences"],"dc:title":["Development of Multiple Microemulsion Eye Drops for Sustained Release of New Glaucoma Drug"],"thesis:degree_discipline":["Pharmaceutical Sciences"],"thesis:degree_level":["Dissertation"],"thesis:degree_name":["Doctor of Philosophy (PhD)"]},"updated_at":"2026-07-24T05:00:33Z"}